Moderna (NASDAQ:MRNA) Given Market Perform Rating at William Blair

William Blair reissued their market perform rating on shares of Moderna (NASDAQ:MRNA) in a research note published on Monday morning,RTT News reports.

Several other analysts have also commented on MRNA. Barclays decreased their price objective on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. Royal Bank of Canada cut their target price on Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Morgan Stanley cut their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus target price of $53.58.

Moderna Trading Up 1.8%

Shares of MRNA opened at $27.05 on Monday. Moderna has a 12 month low of $23.15 and a 12 month high of $158.82. The stock has a fifty day moving average price of $26.32 and a 200-day moving average price of $33.75. The firm has a market cap of $10.46 billion, a PE ratio of -2.91 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the prior year, the business posted ($3.07) EPS. The business’s revenue for the quarter was down 35.3% compared to the same quarter last year. As a group, research analysts forecast that Moderna will post -9.61 EPS for the current year.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently modified their holdings of MRNA. Norges Bank acquired a new stake in shares of Moderna during the 4th quarter valued at about $163,833,000. Voloridge Investment Management LLC grew its position in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after acquiring an additional 1,996,003 shares during the period. FMR LLC grew its position in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after acquiring an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA lifted its stake in Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock valued at $73,447,000 after buying an additional 1,113,455 shares in the last quarter. Finally, SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in Moderna in the 1st quarter valued at about $28,350,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.